4SC AG: 4SC announces Half-Year Report 2024 and provides update
Marketing Authorization Application (MAA) for resminostat (Kinselby) submitted to the European Medicines Agency (EMA…
Marketing Authorization Application (MAA) for resminostat (Kinselby) submitted to the European Medicines Agency (EMA…
Swissmedic has granted Orphan Drug Status for resminostat for treatment of cutaneous T-cell lymphoma (CTCL) ODS benef…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
Removes the requirement to conduct paediatric clinical studies when the development of the medicine is not needed or is…
Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cut…
4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 202…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
The Board of Management of 4SC AG (4SC, FSE Prime Standard: VSC) announced today that according to its best judgment, th…
4SC AG (4SC or "the Company") (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients sufferin…